Dokument: Antineoplastic therapy affects the in vitro phenotype and functionality of healthy human bone marrow-derived mesenchymal stromal cells
| Titel: | Antineoplastic therapy affects the in vitro phenotype and functionality of healthy human bone marrow-derived mesenchymal stromal cells | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=69033 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20250314-101234-2 | |||||||
| Kollektion: | Publikationen | |||||||
| Sprache: | Englisch | |||||||
| Dokumententyp: | Wissenschaftliche Texte » Artikel, Aufsatz | |||||||
| Medientyp: | Text | |||||||
| Autoren: | Scherer, Bo [Autor] Bogun, Lucienne [Autor] Koch, Annemarie [Autor] Jäger, Paul [Autor] Maus, Uwe [Autor] Schmitt, Laura [Autor] Krings, Karina S. [Autor] Wesselborg, Sebastian [Autor] Haas, Rainer [Autor] Schroeder, Thomas [Autor] | |||||||
| Dateien: |
| |||||||
| Stichwörter: | Bone marrow microenvironment, Antineoplastic therapy, MSC, Hematotoxicity, Differentiation | |||||||
| Beschreibung: | While antineoplastic therapies aim to specifically target cancer cells, they may also exert adverse effects on healthy tissues, like healthy hematopoietic stem and progenitor cells (HSPC), leading to hematotoxicity as a common side effect. Mesenchymal stromal cells (MSC) are a major component of the bone marrow (BM) microenvironment, regulating normal hematopoiesis, while their susceptibility to anticancer therapies and contribution to therapy-related hematotoxicity remains largely unexplored. To address this, we investigated the effects of etoposide, temozolomide, 5-azacitidine, and venetoclax on healthy BM-derived MSC functionality. Doses below therapeutic effects of etoposide (0.1–0.25 µM) inhibited cellular growth and induced cellular senescence in healthy MSC, accompanied by an increased mRNA expression of CDKN1A, decreased trilineage differentiation capacity, and insufficient hematopoietic support. Pharmacological doses of 5-azacitidine (2.5 µM) shifted MSC differentiation capacity by inhibiting osteogenic capacity but enhancing the chondrogenic lineage, as demonstrated by histochemical staining and on mRNA level. At the highest clinically relevant dose, neither venetoclax (40 nM) nor temozolomide (100 µM) exerted any effects on MSC but clearly inhibited cellular growth of cancer cell lines and primary healthy HSPC, pointing to damage to hematopoietic cells as a major driver of hematotoxicity of these two compounds. Our findings show that besides HSPC, also MSC are sensitive to certain antineoplastic agents, resulting in molecular and functional alterations that may contribute to therapy-related myelosuppression. Understanding these interactions could be helpful for the development of strategies to preserve BM MSC functionality during different kinds of anticancer therapies. | |||||||
| Rechtliche Vermerke: | Originalveröffentlichung:
Scherer, B., Bogun, L., Koch, A., Jäger, P. S., Maus, U., Schmitt, L., Krings, K. S., Wesselborg, S., Haas, R., Schroeder, T., & Geyh, S. (2024). Antineoplastic therapy affects the in vitro phenotype and functionality of healthy human bone marrow-derived mesenchymal stromal cells. Archives of Toxicology, 99(1), 393–406. https://doi.org/10.1007/s00204-024-03898-w | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 14.03.2025 | |||||||
| Dateien geändert am: | 14.03.2025 |
